Table 2. Parameters of blood lipids and PCSK9 14 days after treatment.
| Parameter | R group | R + E group | E group |
|---|---|---|---|
| TC (mmol/L) | 4.99±1.23 | 4.88±1.45 | 5.75±1.48 |
| TG (mmol/L) | 1.81±0.56 | 1.50±0.63 | 2.32±0.79 |
| HDL-C (mmol/L) | 1.02±0.25 | 1.09±0.23 | 1.10±0.24 |
| LDL-C (mmol/L) | 1.60±0.58 | 1.37±0.62 | 3.17±1.17 |
| PCSK9 (ng/mL) | 383.30±139.87 | 388.50±135.68 | 301.99±112.58 |
| PCSK9 percent change (%) | 31.50±20.11 | 34.80±26.38 | 1.95±11.85 |
All parameters listed above are from post-treatment data. R group, the rosuvastatin group; R + E group, the rosuvastatin plus ezetimibe group; E group, the ezetimibe group; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin kexin type 9.